Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for overseas issuance and listing, specifically requesting details from Libang Pharmaceutical regarding its previous listing on the Jiangsu Equity Exchange and the reasons for its termination [1] - Libang Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with Jefferies, BofA Securities, and HTSC acting as joint sponsors [1] - The CSRC requires Libang Pharmaceutical to clarify the situation of its major shareholders and any significant impacts on the current issuance and listing process [1] Group 2 - The company must provide detailed explanations regarding its equity structure, including past capital increases and share transfer pricing, to ensure compliance with legal regulations [2] - The company is required to clarify the reasons for any capital reductions and the payment situations involved, ensuring that there are no issues of false capital contributions or tax compliance [2] - The company must also disclose the circumstances surrounding its employee stock ownership plan, including the rationale for any pricing discrepancies and compliance with relevant regulations [3] Group 3 - Libang Pharmaceutical is a leading global biopharmaceutical company focused on kidney disease, with a comprehensive portfolio of innovative products and a significant market potential valued in the hundreds of billions of dollars [3] - The company has established a vertically integrated platform that encompasses research and development, production, and commercialization [3]

1月19日，中国证监会公布境外发行上市备案补充材料要求公示(2026年1月12日—2026年1月16日)。证 监会要求礼邦医药说明前期在江苏股权交易中心挂牌的详细情况及终止挂牌原因，是否计划继续推进A 股上市及具体安排，是否存在对本次发行上市产生重大影响的情形。据港交所2025年10月31日披露，礼 邦医药向港交所提交上市申请书，Jefferies、BofA Securities、HTSC为联席保荐人。 同时，证监会要求礼邦医药补充说明以下事项，请律师核查并出具明确的法律意见： 关于股权架构，补充说明：(1)公司历次增资及股权转让价格及定价依据，是否存在入股对价异常的情 况，是否实缴出资，是否存在利益输送，并就公司设立及历次股权变动是否合法合规出具结论性意见； (2)股权架构调整过程中历次减资的原因及对价支付情况，是否涉及虚假出资、抽逃出资，并说明相关 决策程序履行及税费缴纳情况，是否符合《公司法》和税收相关法律法规规定；(3)公司股份回购对 价、定价依据及被回购方所得税缴纳情况；(4)公司取得境内运营实体的交易对价、定价依据、支付手 段、支付期限、定价的公允性，以及上述股权转让环节相关转让方纳税申报义务履行 ...